Alnylam Pharmaceuticals Appoints New Directors, Adjusts Executive Pay
Ticker: ALNY · Form: 8-K · Filed: Mar 5, 2025 · CIK: 1178670
Sentiment: neutral
Topics: board-changes, executive-compensation, governance
Related Tickers: ALNY
TL;DR
Alnylam adds two directors and tweaks exec pay. Board changes are official March 3rd.
AI Summary
Alnylam Pharmaceuticals, Inc. announced on March 3, 2025, changes in its board of directors and executive compensation. Specifically, the company elected two new directors, Dr. Blake J. Wilson and Dr. David E. R. Gray, to its Board of Directors, effective March 3, 2025. Additionally, the company entered into new employment agreements with certain executive officers, including compensation arrangements.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — The filing reports routine corporate governance changes and executive compensation adjustments, which are common and typically do not indicate significant operational risks.
Key Players & Entities
- Alnylam Pharmaceuticals, Inc. (company) — Filer
- Dr. Blake J. Wilson (person) — Newly elected director
- Dr. David E. R. Gray (person) — Newly elected director
- March 3, 2025 (date) — Effective date of director appointments and reporting date
- March 5, 2025 (date) — Filing date
FAQ
Who were the new directors elected to Alnylam Pharmaceuticals' Board?
Dr. Blake J. Wilson and Dr. David E. R. Gray were elected as new directors.
When were the new director appointments effective?
The appointments of Dr. Blake J. Wilson and Dr. David E. R. Gray were effective as of March 3, 2025.
What other significant event is reported in this 8-K filing?
The filing also reports on compensatory arrangements for certain officers.
What is the principal executive office address for Alnylam Pharmaceuticals?
The principal executive offices are located at 675 West Kendall Street, Henri A. Termeer Square, Cambridge, Massachusetts 02142.
What is the SEC file number for Alnylam Pharmaceuticals?
The SEC file number for Alnylam Pharmaceuticals is 001-36407.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 5, 2025 by Dr. Blake J. Wilson regarding ALNYLAM PHARMACEUTICALS, INC. (ALNY).